Ionis Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Ionis PharmaceuticalsDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -49.8% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind rückläufig mit einer durchschnittlichen Rate von 5.6% pro Jahr.

Wichtige Informationen

-49.8%

Wachstumsrate der Gewinne

-49.7%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	-5.6%
Eigenkapitalrendite	-129.8%
Netto-Marge	-49.5%
Letzte Ertragsaktualisierung	31 Mar 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

May 28

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

May 09

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Apr 14

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Mar 18

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Feb 23

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Dec 28

Some Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Analysts Just Made A Major Cut To Next Year's Estimates

Feb 25

Aufschlüsselung der Einnahmen und Ausgaben

Wie Ionis Pharmaceuticals Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGS:IONS Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten
31 Mar 24	777	-385	220
31 Dec 23	788	-366	213
30 Sep 23	615	-409	210
30 Jun 23	631	-309	174
31 Mar 23	576	-329	162
31 Dec 22	587	-270	150
30 Sep 22	875	7	141
30 Jun 22	849	-28	137
31 Mar 22	841	-4	148
31 Dec 21	810	-29	186
30 Sep 21	661	-608	207
30 Jun 21	688	-550	245
31 Mar 21	708	-495	272
31 Dec 20	729	-444	354
30 Sep 20	933	94	299
30 Jun 20	940	145	290
31 Mar 20	959	169	293
31 Dec 19	1,123	281	287
30 Sep 19	821	433	269
30 Jun 19	799	402	278
31 Mar 19	752	366	269
31 Dec 18	600	277	245
30 Sep 18	575	-41	224
30 Jun 18	548	-38	182
31 Mar 18	543	9	138
31 Dec 17	514	19	108
30 Sep 17	507	42	81
30 Jun 17	499	52	64
31 Mar 17	426	-15	52
31 Dec 16	373	-60	49
30 Sep 16	238	-184	44
30 Jun 16	176	-227	42
31 Mar 16	258	-134	40
31 Dec 15	284	-88	37
30 Sep 15	317	14	31
30 Jun 15	312	23	27
31 Mar 15	249	-24	23
31 Dec 14	214	-39	20
30 Sep 14	172	-94	18
30 Jun 14	151	-92	17
31 Mar 14	132	-90	16
31 Dec 13	147	-61	15
30 Sep 13	125	-39	13
30 Jun 13	113	-52	10

Qualität der Erträge: IONS ist derzeit unrentabel.

Wachsende Gewinnspanne: IONS ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: IONS ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 49.8% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von IONS verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: IONS ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (-14.4%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: IONS hat eine negative Eigenkapitalrendite (-129.76%), da es derzeit unrentabel ist.

Ionis Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Ionis Pharmaceuticals, Inc. Announces olezarsen FCS New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed

Independent Director notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Lead Independent Director exercised options to buy US$612k worth of stock.

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS

Founder recently sold US$1.2m worth of stock

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Ionis and AstraZeneca's WAINUA

Insider notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. Shares Positive Clinical Update from Ongoing Trial of Ion582 for Angelman Syndrome

Ionis Presents Positive Two-Year Results from the Phase 2 Open-Label Extension Study of Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Senior Strategic Advisor & Director notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces Positive Olezarsen Topline Results from Phase 3 Study in People with Facilitate Chylomicronemia Syndrome

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Ionis Completes Enrollment in Phase 3 Cardio-TTRansform Study in Patients with TTR-Mediated Amyloid Cardiomyopathy

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Ionis Pharmaceuticals, Inc. Announces Positive Topline, 85-Week Data from the Phase 3 Neuro-Ttransform Study in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces New Data Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Medical Needs After Gene Therapy

Ionis Pharmaceuticals, Inc. Announces Positive Donidalorsen Late-Stage Clinical Progress in HAE

Founder notifies of intention to sell stock

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.2% to US$47.48

Full year 2022 earnings: EPS exceeds analyst expectations

Founder recently sold US$1.0m worth of stock

Ionis Pharmaceuticals, Inc. Announces GSK Has Advanced Bepirovirsen into Phase 3 Development

Ionis Receives FDA Fast Track Designation for Olezarsen in Patients with Familial Chylomicronemia Syndrome

Founder exercised options and sold US$990k worth of stock

Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Ionis Pharmaceuticals, Inc. Announces European Medicines Agency Accepts Marketing Authorization Application of Tofersen to Treat Rare, Genetic Form of ALS

Consensus forecasts updated

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

Ionis Pharmaceuticals, Inc. Announces Positive Data from GSK's Phase 2b Clinical Study of Bepirovirsen

Ionis Pharmaceuticals, Inc. Presents Positive Phase 2 Data in Patients with IgA Nephropathy At American Society of Nephrology's Kidney Week 2022

Ionis Pharmaceuticals, Inc. Announces Positive Results from Fesomersen Development Program

Oxford Properties Group, Inc. acquired 18.4-Acre Life Science Campus and Corporate Headquarters of Ionis Pharmaceutical in San Diego from Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS).

Ionis Pharmaceuticals Looks Good For The Long Term

Ionis plans for new manufacturing site in California to support pipeline

Ionis Pharmaceuticals, Inc. Provides Update on Development Program Evaluating PCSK9 Antisense Medicine for the Treatment of Hypercholesterolemia

Ionis Pharmaceuticals, Inc. Presents Positive Results from Phase 3 Neuro-Ttransform Study At International Symposium on Amyloidosis

Ionis: 2 Drug Advancements With Potential Firsts

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022